Panacos Pharmaceuticals (PANC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Panacos Pharmaceuticals (PANC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (32)	8/1/2007 1:31:39 PM
From: tuck	Read Replies (1) of 53

Hmm. Digging a little farther into the CC, I see they are still slow on the oral formulation issue, and P3 seems to be pushed out another quarter. That, and the bioavailability problems with the 1st generation budding inhibitor, causing them to drop it and go with a 2nd generation budding inhibitor, appears to be behind the fresh drop to 52 week lows. See also: fool.com Clearly the market is beginning to doubt their ability to resolve the formulation issues. The move to the 2nd generation budding inhibitors doesn't bother me as much. Holding, but not adding yet. Cheer, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next